Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
- BI Launches Global Venture Fund
April 26, 2010
- Isentress Recommended for Lack of Effects on Lipids: Dr Hanabusa
April 26, 2010
- MCI Provides Tablet PCs to All MRs from Benesis
April 19, 2010
- Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
April 19, 2010
- GSK to Disclose Payments to Physicians Made in 2009 and Onward
April 19, 2010
- 637 Monitors Certified in 2nd JCROA Monitor Certification Test
April 19, 2010
- Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
April 19, 2010
- Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
April 19, 2010
- Taiyo Can No Longer Be Family-Owned Company: President Aratani
April 19, 2010
- AnGes MG to Codevelop NF-κB Decoy with Shionogi
April 19, 2010
- Ajinomoto Pharm. to Enter Southeast Asian Market
April 19, 2010
- DB on Medicinal Plants Posted on NIBIO Website
April 19, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…